Elinzanetant (2) – Lynkuet®
Vasomotor symptoms associated with breast cancer
Characteristics
| Start date | 01.04.2026 |
|---|---|
| Resolution | 01.10.2026 – active procedure |
| INN | Elinzanetant |
| Brand name | Lynkuet® |
| Pharm. company | Bayer Vital GmbH |
| G-BA Procedure ID | D-1300 |
| Therapeutic area | Other diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions